| NCT01912534 | Hypertrophic Cardiomyopathy | Drug: Valsartan|Drug: Placebo | New England Research Institutes|National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 2014-04-01 | 2016-05-16 |
| NCT00446524 | Hypertension | Drug: Valsartan + Amlodipine besilate | Novartis | Phase 3 | 2007-02-01 | 2012-05-06 |
| NCT01115972 | Healthy|Pharmacokinetics of Valsartan | Drug: ASP1585|Drug: valsartan | Astellas Pharma Inc | Phase 1 | 2010-03-01 | 2010-05-26 |
| NCT00208767 | Carotid Artery Diseases|Atherosclerosis | Drug: Valsartan|Drug: Placebo | Emory University | Phase 2 | 2005-02-01 | 2015-11-09 |
| NCT01425411 | Hypertension|Left Ventricular Hypertrophy | Drug: valsartan | Mustafa Kemal University|Novartis Pharmaceuticals | Phase 4 | 2006-11-01 | 2011-08-29 |
| NCT02631031 | Healthy Normotensive Volunteers | Drug: Valsartan | Ain Shams University | Phase 1 | 2015-11-01 | 2016-07-11 |
| NCT00140790 | Hypertension | Drug: valsartan | Kumamoto University | Phase 4 | 2006-08-01 | 2016-02-25 |
| NCT01070043 | Hypertension|High Blood Pressure | Drug: Amlodipine 5mg/Valsartan 80 mg|Drug: Valsartan | Novartis | Phase 4 | 2009-06-01 | 2011-09-13 |
| NCT00657241 | Hypertension | Drug: carvedilol|Drug: valsartan | State University of New York at Buffalo|GlaxoSmithKline | Phase 3 | 2008-04-01 | 2010-06-30 |
| NCT02690974 | Hearth Failure With Reduced Ejection Fraction (HFrEF) | Drug: LCZ696 (sacubitril/valsartan) | Novartis Pharmaceuticals|Novartis | Phase 4 | 2016-03-09 | 2017-02-28 |
| NCT00149227 | Hypertension|Ischemic Heart Disease|Congestive Heart Failure|Stroke | Drug: Valsartan|Drug: Non-ARB | Kyoto Prefectural University of Medicine | Phase 4 | 2004-01-01 | 2012-12-09 |
| NCT02815657 | Type 2 Diabetes | Drug: SP2086|Drug: Valsartan | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 | 2013-04-01 | 2016-06-23 |
| NCT01541189 | Hypertension | Drug: Valsartan | Novartis Pharmaceuticals|Novartis | Phase 4 | 2012-02-01 | 2017-03-17 |
| NCT01805804 | First Time Dual Chamber Pacemaker Implantation | Drug: placebo/valsartan | Medical University of Silesia|Polpharma Pharmaceutical Company | Phase 4 | 2017-01-01 | 2017-01-01 |
| NCT01681576 | Salt-sensitive Hypertension | Drug: Valsartan|Drug: LCZ696 | Novartis Pharmaceuticals|Novartis | Phase 2 | 2012-08-01 | 2015-10-12 |
| NCT02916160 | Chronic Heart Failure|Sleep Apnea Syndrome | Drug: SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO庐) | University Hospital, Montpellier | | 2016-09-01 | 2016-09-23 |
| NCT00809926 | Stage 2 Hypertension | Drug: Valsartan/aliskiren|Drug: Valsartan | Novartis | Phase 4 | 2009-01-01 | 2011-03-31 |
| NCT01095822 | Diabetes Mellitus | Drug: Aliskiren + Valsartan | HeartDrug Research LLC|Novartis | Phase 4 | 2010-03-01 | 2010-03-29 |
| NCT00457626 | Hypertension | Drug: Valsartan | Novartis Pharmaceuticals|Novartis | Phase 3 | 2007-04-01 | 2016-11-16 |
| NCT01001572 | Essential Hypertension | Drug: Valsartan/amlodipine 160/5 mg|Drug: Valsartan 160 mg|Drug: Placebo | Novartis | Phase 3 | 2009-09-01 | 2011-05-18 |
| NCT01850160 | Hypertension | Drug: GROUP A: Valsartan plus Chlorthalidone|Drug: GROUP B: Valsartan|Drug: GROUP C: Chlorthalidone | Farma de Colombia SA | Phase 3 | 2013-04-01 | 2016-01-25 |
| NCT00416468 | Healthy | Drug: Aliskiren|Drug: Valsartan | Novartis | Phase 1 | 2006-11-01 | 2007-06-21 |
| NCT00416728 | Healthy | Drug: Aliskiren|Drug: Valsartan | Novartis | Phase 1 | 2006-11-01 | 2007-06-21 |
| NCT00415883 | Healthy | Drug: Valsartan | Novartis | Phase 1 | 2006-07-01 | 2007-06-21 |
